Advertisement
Advertisement
TOPIC

Made in China 2025

Made in China 2025
Launched by Premier Li Keqiang in 2015, the “Made in China 2025" strategy aims to guide the country’s industrial modernisation, including the substitution of foreign technology with innovation developed on the mainland.
A battery assembly line at Leapenergy, a unit of Leapmotor, in Huzhou, Zhejiang province. Photo: Reuters
China trade

China’s expanding industrial strategy

The country’s industrial strategy has shifted from targeting specific sectors towards covering all layers of production.

Biomedicine: Companies

China biotech deals hit record as innovative drugs draw global interest

Biomedicine: Companies

Global drug giants double down on China amid push for self-reliant supply chains

Biomedicine: Companies

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

The logo of Sino Biopharmaceutical is seen on a building in Beijing, April 22, 2021. Photo: VCG via Getty Images
China technology

Xiaomi tests humanoid robots as firm plans to deploy ‘large number’ in 5 years

Xiaomi robots operated autonomously for three continuous hours, successfully completing assembly tasks without human intervention.

Biomedicine: Companies

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Advertisement
Advertisement
Advertisement
China economy

Opinion | How ‘little giants’ help China defend its manufacturing dominance

Support for ‘little giants’ and other specialised SMEs remains a vital part of the long-term strategy to bolster China’s global manufacturing.

videocam
A robot by ‘little giant’ tech firm Unitree Robotics dancing at the TechShare booth during the International Robot Exhibition 2025 (iREX2025) in Tokyo, Japan, on December 3. Photo: EPA
Biomedicine: Industry Trends

After boost from viral dance challenge, Chinese medicine firm’s shares languish

Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.

China economy

Opinion | How the next China shock is shaping hearts and minds

No longer confined to trade and technology, competition between China and the West is now playing out in the realm of cultural imagination.

videocam
Biomedicine: Industry Trends

Capital injection: China backs AI drug makers in self-reliance drive

A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.

The recent wave of investment in AI drug development aligns with Beijing’s drive for technological self-sufficiency. Photo: Shutterstock
Biomedicine: Companies

Chinese healthcare firms expand overseas to support growing expat community

Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.

Distinct Healthcare raised HK$284.53 million from its initial public offering in Hong Kong last week. Photo: Handout
Biomedicine: Industry Trends

Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal

The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.

IPO

Morgan Stanley sees another record year for Hong Kong IPOs as pipeline hits 450

Mainland China’s issuers will still dominate city’s IPO market, executive says, but US and Southeast Asian companies are also joining in.

Biomedicine: Geopolitics

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

Leung Chuen-yan, partner for healthcare investment at Value Partners Group. Photo: Edmond So
Biomedicine: Industry Trends

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Swiss drugmaker Novartis has gained global rights over SciNeuro’s novel amyloid beta targeted antibody programme. Photo: Reuters
Biomedicine: Industry Trends

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

Biomedicine: Companies

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Advertisement
Advertisement
Advertisement
Biomedicine: Industry Trends

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

The total pet population in China reached 430 million in 2024, with nearly one-third of urban cats classified as obese, according to the China Pet Industry Association. Photo: Shutterstock
China manufacturing

China’s next decade to cement status as hi-tech manufacturing power: reports

The coming 10 years will see significant advances in cutting-edge sectors, reinforcing industrial dominance, according to new reports.

videocam
7
Mainland China

Chinese firms flock to Dubai free zones to navigate trade barriers, expand reach

JD.com, CNBM, carmakers and hundreds of other Chinese companies use the hub to reach consumers across Asia, Africa and Europe.

Biomedicine: Industry Trends

China’s rising biotech clout on show in flurry of billion-dollar licensing deals

A burst of overseas licensing pacts is spotlighting China’s biotech sector, as Jacobio, Coherent Biopharma and Harbour BioMed land deals.

The latest transactions reflect a broader pattern of multinational drugmakers turning to Chinese biotechs for pipeline replenishment. Photo: Shutterstock
China economy

Opinion | Arguing about China’s overcapacity overlooks its drive for clean energy

What is often described as overcapacity is the outcome of a development strategy that treats energy as the foundation of economic capability.

videocam
Fields of solar panels at a power station in Weining, Guizhou province, in China on July 3. Photo: Xinhua
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Biomedicine: Industry Trends

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

Mainland China

Can rising lithium costs save China’s energy storage firms from a price war?

China’s battery makers raise prices amid lithium rebound and global AI energy demand.

Deegares says it is raising prices of lithium batteries by 15 per cent. Photo: Handout
Biomedicine: Policy

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

The commercial insurance formulary covers some medicines that are not yet eligible for reimbursement under the country’s National Reimbursement Drug List. Photo: Shutterstock
Biomedicine: Companies

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

Robotics

China’s Unitree teases platform allowing users to control robots via smartphones

Hangzhou robotics unicorn’s platform is designed to bring embodied intelligence into everyday life.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement